- FDA approves Actavis epilepsy drug
- Dr. Reddy's launches generic epilepsy drug
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic epilepsy drug made by Wockhardt, the company said.
Wockhardt, based in India, announced the approval of lamotrigine extended-release tablets in the 25-mg, 50-mg, 100-mg, 200-mg and 300-mg strengths.
The drug is a generic version of GlaxoSmithKline's Lamictal XR. The U.S. market for the drug is about $250 million, according to IMS Health.